Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNα and autologous IL-2-activated lymphocytes)

This publication has 18 references indexed in Scilit:

• Metastatic renal‐cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring
  International Journal of Cancer, 1994
• Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2
  Clinical and Experimental Immunology, 1993
• Expansion of Peripheral Blood Natural Killer Cells Correlates with Clinical Outcome in Cancer Patients Receiving Recombinant Subcutaneous lnterleukin-2 and Interferon-α-2
  Tumor Biology, 1993
• Bioavailability of interleukin-2 after reconstitution with albumin
  The Lancet, 1992
• Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2
  Annals of Oncology, 1992
• Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma
  Cancer Immunology, Immunotherapy, 1991
• Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: Correlation with clinical toxicity
  Cancer Immunology, Immunotherapy, 1991
• Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells
  Cancer Immunology, Immunotherapy, 1990
• Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry
  Cytometry, 1990
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
  Journal of Clinical Oncology, 1989